Perpetual Ltd Invests $19.94 Million in Humana Inc. $HUM

Perpetual Ltd bought a new position in shares of Humana Inc. (NYSE:HUM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 77,843 shares of the insurance provider’s stock, valued at approximately $19,938,000. Perpetual Ltd owned about 0.06% of Humana as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of HUM. CoreCap Advisors LLC increased its holdings in shares of Humana by 54.4% in the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Rosenberg Matthew Hamilton boosted its stake in Humana by 136.0% during the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after buying an additional 68 shares during the last quarter. Mather Group LLC. bought a new position in Humana during the third quarter valued at approximately $34,000. Private Wealth Management Group LLC grew its holdings in Humana by 47.5% during the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after buying an additional 48 shares in the last quarter. Finally, Larson Financial Group LLC increased its stake in Humana by 114.1% in the 3rd quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock worth $40,000 after acquiring an additional 81 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

Shares of NYSE:HUM opened at $178.05 on Friday. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 0.70. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $315.35. The company has a market capitalization of $21.38 billion, a price-to-earnings ratio of 18.13, a PEG ratio of 1.90 and a beta of 0.44. The firm’s 50-day moving average is $182.32 and its 200 day moving average is $235.38.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.01) by $0.05. The business had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Research analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Friday, March 27th. Humana’s dividend payout ratio is 36.05%.

Analysts Set New Price Targets

Several analysts have recently issued reports on HUM shares. Royal Bank Of Canada cut Humana from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $322.00 to $189.00 in a report on Thursday, February 12th. Wells Fargo & Company reduced their price target on shares of Humana from $290.00 to $206.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 18th. Cantor Fitzgerald decreased their price target on shares of Humana from $290.00 to $201.00 and set a “neutral” rating on the stock in a research note on Thursday, February 12th. Morgan Stanley set a $146.00 price objective on shares of Humana in a research report on Thursday, February 12th. Finally, Oppenheimer set a $250.00 price objective on shares of Humana in a research note on Thursday, February 12th. Seven analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $225.48.

Insider Buying and Selling

In other Humana news, insider Sanjay K. Shetty bought 810 shares of Humana stock in a transaction on Monday, February 23rd. The shares were acquired at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the purchase, the insider directly owned 11,657 shares in the company, valued at approximately $2,158,992.97. This trade represents a 7.47% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.20% of the stock is owned by company insiders.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.